Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR4 | P51679 | 20/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4704266 | 0.94 | CCR4 (0.65) | CCR4 | |
| SCHEMBL4703606 | 0.94 | CCR4 (0.65) | CCR4 | |
| SCHEMBL4700474 | 0.93 | CCR4 (0.64) | CCR4 | |
| SCHEMBL4703190 | 0.93 | CCR4 (0.64) | CCR4 | |
| SCHEMBL4701051 | 0.92 | CCR4 (0.62) | CCR4 | |
| SCHEMBL4699584 | 0.91 | CCR4 (0.61) | CCR4 | |
| SCHEMBL4700933 | 0.90 | CCR4 (0.65) | CCR4 | |
| SCHEMBL4700937 | 0.90 | CCR4 (0.65) | CCR4 | |
| SCHEMBL4702981 | 0.88 | CCR4 (0.66) | CCR4 | |
| SCHEMBL1731930 | 0.87 | CCR4 (0.65) | CCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1633729-B1 | SULPHONAMIDE COMPOUNDS THAT MODULATE CHEMOKINE RECEPTOR ACTIVITY (CCR4) | ASTRAZENECA AB (SE) | 2008-07-30 | — | — | EP | claimed |
| US-20060122195-A1 | Sulphonamide compounds that modulate chemokine receptor activity (ccr4) | ASTRAZENECA AB (SE) | 2006-06-08 | — | — | US | claimed |
| EP-1633729-A1 | SULPHONAMIDE COMPOUNDS THAT MODULATE CHEMOKINE RECEPTOR ACTIVITY (CCR4) | AstraZeneca AB (SE) | 2006-03-15 | — | — | EP | claimed |
| WO-2004108692-A1 | SULPHONAMIDE COMPOUNDS THAT MODULATE CHEMOKINE RECEPTOR ACTIVITY (CCR4) | ASTRAZENECA AB (SE) | 2004-12-16 | — | — | WO | claimed |
| EP-1633729-B1 | SULPHONAMIDE COMPOUNDS THAT MODULATE CHEMOKINE RECEPTOR ACTIVITY (CCR4) | ASTRAZENECA AB (SE) | 2008-07-30 | — | — | EP | disclosed |
| US-20060122195-A1 | Sulphonamide compounds that modulate chemokine receptor activity (ccr4) | ASTRAZENECA AB (SE) | 2006-06-08 | — | — | US | disclosed |
| EP-1633729-A1 | SULPHONAMIDE COMPOUNDS THAT MODULATE CHEMOKINE RECEPTOR ACTIVITY (CCR4) | AstraZeneca AB (SE) | 2006-03-15 | — | — | EP | disclosed |
| WO-2004108692-A1 | SULPHONAMIDE COMPOUNDS THAT MODULATE CHEMOKINE RECEPTOR ACTIVITY (CCR4) | ASTRAZENECA AB (SE) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122195-A1 | Sulphonamide compounds that modulate chemokine receptor activity (ccr4) | CCR4, CCR1, CCR3 | CCR4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.